Applied UV Receives Notification of Patent Allowance from European Patent Office for Pathogen Destroying Devices

Rhea-AI Summary

Applied UV (NasdaqCM:AUVI) announced a significant milestone with the European Union Patent Office allowing a patent for its core pathogen-destroying device. This patent strengthens the company's Intellectual Property (IP) portfolio aimed at combating healthcare-acquired infections (HAIs) in high-traffic areas like hospitals and hotels. With this addition, SteriLumen now holds multiple patents across the US and Europe, enhancing its potential for commercialization. Independent lab tests show the SteriLumen system effectively eliminates up to 99.99% of pathogens, addressing urgent global health challenges.

Positive

• Patent allowed for core pathogen-destroying device, enhancing IP portfolio.
• Strengthens commercialization opportunities across Europe.
• Independent lab tests confirm effectiveness in killing pathogens, including coronavirus.

Negative

• None.

Adds to Company's Patent Protecting Disinfection Technology Portfolio Addressing Global Challenge of HAI's and Pathogen Spread in Public Spaces

MOUNT VERNON, NY / ACCESSWIRE / January 25, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") to destroy pathogens safely, thoroughly, and automatically, announced that the European Union Patent Office has notified the Company that a patent has been allowed for the invention of its core pathogen destroying device.

"The issuance of a new patent for our innovative disinfection device technology is an important milestone for the Company as we continue expanding our IP portfolio to address the vexing and costly global challenge of infection prevention," said Max Munn, President of Applied UV. "Additionally, having this additional patent protection will support our commercialization and partnering opportunities throughout Europe."

As of January 25, 2021, SteriLumen owned eight issued patents in the United States; two issued patents in the European Union, as well as several pending patent applications in China, the Gulf Cooperation Council (GCC), Japan, South Korea, Taiwan, and others. The issued patents and pending patent applications cover various aspects of the SteriLumen Disinfecting System.

SteriLumen devices are designed to substantially reduce pathogens that may cause healthcare-acquired infections ("HAIs"), and are primarily targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces. The SteriLumen Disinfecting System uses UVC LEDs in a variety of designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. Additionally, the Company has a patent for an "in-drain device" that addresses this critical pathogen intensive location.

In a report provided to the Company dated June 30, 2020, ResInnova Laboratories ("ResInnova"), an International Antimicrobial Council certified laboratory, found the SteriLumen Disinfecting System to be effective in killing OC43 human coronavirus which is a common surrogate for SARS-CoV-2, the virus that causes COVID-19. For additional information about the findings in the independent laboratory report, please visit www.SteriLumen.com.

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen develops disinfection devices and technology that destroy pathogens that may cause viruses and health care acquired infections (HAIs). SteriLumen disinfection technology applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically. SteriLumen devices were tested at an independent laboratory that found the SteriLumen mirror and drain to be greater than 97% and 99.99%, respectively, effective in killing the OC43 human coronavirus, a strain of human coronavirus that is genetically similar to SARS-CoV-2. SteriLumen was formed in 2016 by the founders of MunnWorks to provide novel, easy to deploy and effective devices to protect vulnerable populations from dangerous infections, providing a compelling solution for the hospitality space and a solid path to entering the healthcare market. MunnWorks manufactures fine mirrors specifically for the hospitality industry. Our goal at Munn Works is to contribute to the creation of what our design industry clients seek: manufacturing extraordinary, framed mirrors.

For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; and, https://munnworks.com/.

Forward-Looking Statements

The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.

Applied UV Investor Relations

TraDigital IR

Kevin McGrath
TraDigital IR
+1-646-418-7002
kevin@tradigitalir.com

SOURCE: Applied UV, Inc.

View source version on accesswire.com:
https://www.accesswire.com/625746/Applied-UV-Receives-Notification-of-Patent-Allowance-from-European-Patent-Office-for-Pathogen-Destroying-Devices

FAQ

What is the recent patent announcement by Applied UV (AUVI)?

Applied UV announced that the European Patent Office allowed a patent for its core pathogen-destroying device, enhancing its IP portfolio.

How does Applied UV's SteriLumen technology work?

SteriLumen technology utilizes UVC LEDs to destroy pathogens in high-traffic areas within hospitals and commercial spaces.

What effectiveness has been reported for SteriLumen devices against pathogens?

Independent lab tests found SteriLumen devices effective in killing over 99.99% of pathogens, including the OC43 human coronavirus.

How many patents does Applied UV currently hold?

As of the announcement, SteriLumen holds eight issued patents in the US and two in the European Union, along with several pending applications.

When was the patent allowance for Applied UV announced?

The patent allowance was announced on January 25, 2021.